[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565297":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":23,"locations":30,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Anhui Provincial Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"healthy control",null,"By analyzing the Raman signals of peripheral serum from normal controls, unique signal characteristics specific to ovarian cancer patients are identified through comparative analysis with the control group.",[13],"Other: No intervention",{"label":15,"type":10,"description":16,"interventionNames":17},"Ovarian cancer group","Extract information from blood samples of ovarian cancer patients, specifically identifying cancer and non-cancer signals to construct a statistical algorithm model for the early diagnosis of ovarian cancer.",[13],[19],{"type":20,"name":21,"description":21,"armGroupLabels":22,"otherNames":10},"OTHER","No intervention",[15,9],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Ying Zhou, MD","CONTACT","_8613865901025","caddiezy@ustc.edu.cn",{"name":25,"role":26,"phone":10,"phoneExt":10,"email":28},[31],{"facility":32,"status":33,"city":34,"state":35,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Anhui Provincal Hospital","RECRUITING","Hefei","Anhui","China","CN",{"type":39,"coordinates":40},"Point",[41,42],117.28083,31.86389,{"lat":42,"lon":41},[45],{"name":25,"role":26,"phone":46,"phoneExt":10,"email":28},"+8613865901025",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100565297","ultrasensitive-sers-platform-with-highly-efficient-enrichment-of-analyte-for-screening-and-diagnosis-of-epithelial-ovarian-cancer-100565297",false,"NCT06640348","Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer","Inclusion Criteria:\n\n1. The subjects understand the trial process, sign the informed consent form, voluntarily participate in the study, and are capable of following the protocol;\n2. Aged 18 to 70 (inclusive):\n\nCancer group: Ovarian cancer patients (50 cases of high-grade serous ovarian cancer, 15 cases of low-grade serous ovarian cancer, 20 cases of endometrioid ovarian cancer, 20 cases of clear cell carcinoma) i. All ovarian cancer patients are initial treatment patients with complete clinical data; ii. Patients have an ECOG performance status score of 0-3 and a life expectancy of more than 6 months; iii. Subjects consent to blood sample collection for SERS analysis (provided free of charge); iv. Good organ function.\n\nNormal control group: (20 cases) i. Normal control subjects are patients undergoing surgery for benign diseases; ii. Patients have complete clinical data; iii. Subjects have not undergone any radical treatment for the benign lesion prior to blood collection.\n\nExclusion Criteria:\n\n1. Severe or uncontrolled diseases, including but not limited to: uncontrollable nausea and vomiting, gastrointestinal diseases that may interfere with drug absorption and metabolism, mental illnesses affecting the patient's ability to sign the informed consent form, a history of severe cardiovascular disease, infectious diseases (such as syphilis, AIDS, active hepatitis C, or active hepatitis B), infectious conditions (such as abscesses), or active rheumatic diseases, etc.;\n2. A history of blood transfusion within 4 weeks prior to the study;\n3. Pregnant, postpartum, or breastfeeding patients, or patients planning to become pregnant during the study treatment;\n4. Patients with a history of other tumors;\n5. The investigator deems the subject unsuitable for participation in this clinical study.",true,"FEMALE","18 Years","70 Years",{"count":60,"type":61},70,"ESTIMATED","OBSERVATIONAL","This project is an open, single-center, prospective study aimed at developing high-sensitivity, high-specificity enrichment SERS chips using femtosecond laser processing technology. It involves extracting information from blood samples of ovarian cancer patients and normal controls, specifically identifying cancer and non-cancer signals. The study will construct a statistical algorithm model for the early diagnosis of ovarian cancer, enabling early identification and intervention for ovarian cancer patients.",[65],"Ovarian Cancer, Epithelial","2024-10-11",{"date":68,"type":69},"2024-10-15","ACTUAL",{"date":71,"type":61},"2025-01-01",{"date":73,"type":61},"2030-12-31",{"name":5,"class":6},1]